ArticleCost effectiveness and resource allocation : C/E2026
Epidemiological and economic impact of pre-exposure prophylaxis with targeted immunotherapies for COVID-19 among immunosuppressed patients in Argentina.
Article in Cost effectiveness and resource allocation : C/E, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSome immunosuppressive disorders have shown substantially lower protection after COVID-19 vaccination against severe outcomes. Therefore, pre-exposure prophylaxis is proposed. Targeted immunotherapy with monoclonal antibodies represents an option for preventing severe COVID-19. However, there is a lack of epidemiological and economic information on pre-exposure prophylaxis with targeted immunotherapies against COVID-19 among immunosuppressed patients. Thus, this study aims to identify and estimate the size of target population and direct medical costs related to pre-exposure prophylaxis with targeted immunotherapies against COVID-19 among the immunosuppressed adult population, and to explore the short-term economic impact of introducing tixagevimab–cilgavimab (AZD7442) for pre-exposure prophylaxis from the social security perspective in Argentina. This perspective was chosen due to the broad coverage of Argentina’s social security system, ensuring a representative framework for cost and access analysis.
methodsThrough a four-step approach, we: 1) identified the immunosuppressed adult potential target population that could be eligible for pre-exposure prophylaxis with targeted immunotherapies in Argentina; 2) estimated direct medical costs associated with pre-exposure prophylaxis and COVID-19 management using a micro-costing approach; and 3) explore a cost analysis for the case of tixagevimab–cilgavimab 600 mg (assuming an ex-factory price of $950 per pack) from the social security perspective in Argentina, considering 0% and 100% pre-exposure prophylaxis uptake scenarios. Costs were expressed in American dollars ($) as of November 2022 (exchange rate: 130.8 Argentinian pesos = 1 American dollar).
resultsWe estimated that 12,788 patients with target conditions (approximately 40 per 100,000 adults) would be candidates for receiving this therapy in Argentina. In terms of costs, the 100% uptake scenario accounts for total annual savings of approximately $ 121,902.7 in outpatient and hospitalization COVID-19-related costs. Also, tixagevimab–cilgavimab acquisition and administration costs represented an annual incremental cost of $24,415,617 ($1,918.5 per patient year). Finally, the net cost difference between the 100% and 0% uptake scenarios were estimated at $24,254,732.3 ($1,896.6 per patient year).
conclusionThis study provides crucial information for local and regional decision-makers to guide informed assessment of a potential coverage of pre-exposure prophylaxis with targeted immunotherapy among the immunosuppressed population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.